Author

F. Seker-Polat

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. Cingoz· 2 shared A. P. Cribbs· 2 shared T. Bagci-Onder· 2 shared A. C. Aksu· 1 shared A. Daneshkhah· 1 shared A. Kayabolen· 1 shared B. Isik· 1 shared C. Acilan· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Cingoz

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Depletion of lamins B1 and B2 alters chromatin mobility and induces differential gene expression by a mesoscale-motion dependent mechanism

E. M. Pujadas, X. Wei, N. Acosta, L. Carter, J. Yang, L. Almassalha, A. Daneshkhah, S. S. P. Rao, V. Agrawal, F. Seker-Polat, E. L. Aiden, M. T. Kanemaki, V. Backman, M. Adli

This study shows that depleting lamins B1 and B2 changes chromatin mobility and gene expression through mesoscale-motion dependent mechanisms.

bioRxiv · Jun 26, 2023 · PreprintBioengineering

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

A. Kayabolen, E. Yilmaz, G. N. Sahin, F. Seker-Polat, A. Cingoz, B. Isik, S. Acar, S. Karahuseyinoglu, H. Wakimoto, D. P. Cahill, I. Solaroglu, A. P. Cribbs, U. Oppermann, T. Bagci-Onder

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology